Video
Metastatic urothelial carcinoma: Is addition of more therapies to treatment regimens beneficial?
Author(s):
Shilpa Gupta, MD, discusses several recent studies in the metastatic urothelial carcinoma space.
Video Player is loading.
In this video, Shilpa Gupta, MD, discusses how recent research appears to indicate that the addition of more agents is not beneficial to patients undergoing treatment for metastatic urothelial carcinoma. Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.
Related Videos
BLUES trial: Silicone stents may improve patient care
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
Jim Hu, MD, on urinary continence recovery across RARP techniques
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
Mohit Khera, MD, on the impact of penile prosthesis implant on mental health
Special Report: Tips for PCPs on evaluating prostate cancer risk
Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
Special Report: Tailoring prostate cancer care for older adults
Related Content
